ATE496623T1 - Oxcarbazepin-zubereitungen für kontrollierte freisetzung mit sigmoidalem freisetzungsprofil - Google Patents

Oxcarbazepin-zubereitungen für kontrollierte freisetzung mit sigmoidalem freisetzungsprofil

Info

Publication number
ATE496623T1
ATE496623T1 AT07760656T AT07760656T ATE496623T1 AT E496623 T1 ATE496623 T1 AT E496623T1 AT 07760656 T AT07760656 T AT 07760656T AT 07760656 T AT07760656 T AT 07760656T AT E496623 T1 ATE496623 T1 AT E496623T1
Authority
AT
Austria
Prior art keywords
release
sigmoidal
oxcarbazepine
preparations
controlled release
Prior art date
Application number
AT07760656T
Other languages
English (en)
Inventor
Padmanabh Bhatt
Argaw Kidane
Kevin Edwards
Original Assignee
Supernus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38324170&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE496623(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Supernus Pharmaceuticals Inc filed Critical Supernus Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE496623T1 publication Critical patent/ATE496623T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/56—Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT07760656T 2006-04-26 2007-04-13 Oxcarbazepin-zubereitungen für kontrollierte freisetzung mit sigmoidalem freisetzungsprofil ATE496623T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79483706P 2006-04-26 2006-04-26
PCT/US2007/066643 WO2007127630A1 (en) 2006-04-26 2007-04-13 Controlled released preparations of oxcarbazepine having sigmoidal release profile

Publications (1)

Publication Number Publication Date
ATE496623T1 true ATE496623T1 (de) 2011-02-15

Family

ID=38324170

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07760656T ATE496623T1 (de) 2006-04-26 2007-04-13 Oxcarbazepin-zubereitungen für kontrollierte freisetzung mit sigmoidalem freisetzungsprofil

Country Status (11)

Country Link
US (16) US7722898B2 (de)
EP (2) EP2359830B1 (de)
JP (2) JP5253381B2 (de)
CN (1) CN101489560B (de)
AT (1) ATE496623T1 (de)
AU (1) AU2007242984B2 (de)
CA (1) CA2597740C (de)
DE (1) DE602007012236D1 (de)
ES (2) ES2360423T3 (de)
MX (1) MX2008013675A (de)
WO (1) WO2007127630A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007122635A2 (en) * 2006-04-26 2007-11-01 Astron Research Limited Controlled release formulation comprising anti-epileptic drugs
CA2597740C (en) 2006-04-26 2012-10-16 Supernus Pharmaceuticals, Inc. Modified-release preparations containing oxcarbazepine and derivatives thereof
EP2429492B1 (de) * 2009-05-13 2014-06-25 Basf Se Feste pharmazeutische Zubereitungen enthaltend Copolymere auf Basis von Polyethern in Kombination mit wasserschwerlöslichen Polymeren
EP2540318B1 (de) 2010-02-22 2018-10-24 Daiichi Sankyo Company, Limited Feststoffpräparat mit verzögerter freisetzung zur oralen verabreichung
EP2540294B1 (de) * 2010-02-22 2016-08-03 Daiichi Sankyo Company, Limited Feststoffpräparat mit verzögerter freisetzung zur oralen verabreichung
EP2632584B1 (de) 2010-10-26 2017-08-09 Capsugel Belgium NV Verfahren zur herstellung von bulk-enterale kapselhüllen
EA032906B1 (ru) 2010-12-22 2019-08-30 Пэдью Фарма Л.П. Твердая лекарственная форма с контролируемым высвобождением и способы ее получения и применения
KR101458334B1 (ko) 2010-12-23 2014-11-04 퍼듀 퍼머 엘피 탬퍼 저항성 고체 경구 투여 형태
US10525010B2 (en) 2012-05-02 2020-01-07 Capsugel Belgium Nv Aqueous dispersions of controlled release polymers and shells and capsules thereof
TWI566786B (zh) 2012-09-03 2017-01-21 第一三共股份有限公司 含有氫化嗎啡酮鹽酸鹽之經口用徐放性醫藥組成物
CN105120846B (zh) 2013-02-05 2019-10-18 普渡制药公司 抗篡改的药物制剂
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
WO2015063670A1 (en) 2013-10-30 2015-05-07 Wockhardt Limited Solid oral modified-release composition comprising oxcarbazepine or a pharmaceutically acceptable salt thereof
US20160256399A1 (en) 2013-11-04 2016-09-08 Capsugel Belgium Nv Methods and systems for improved bioavailability of active pharmaceutical ingredients including esomeprazole
CN103948552A (zh) * 2014-04-22 2014-07-30 青岛市中心医院 一种奥卡西平控释片及其制备方法
CN104116715A (zh) * 2014-08-08 2014-10-29 上海奥科达生物医药科技有限公司 一种高载药量的奥卡西平缓释颗粒剂及其制备方法
TWI782906B (zh) 2016-03-04 2022-11-11 日商大鵬藥品工業股份有限公司 惡性腫瘤治療用製劑及組合物
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
JP7012660B2 (ja) 2016-04-01 2022-02-14 ノームズ テクノロジーズ インコーポレイテッド リン含有修飾イオン性液体
CN110915037B (zh) 2017-07-17 2023-11-07 诺姆斯科技公司 含磷电解质
WO2019181876A1 (ja) * 2018-03-19 2019-09-26 大鵬薬品工業株式会社 アルキル硫酸ナトリウムを含む医薬組成物
US11980622B1 (en) 2020-06-17 2024-05-14 Apotex Inc. Oxcarbazepine extended release dosage form
CN112590738B (zh) * 2020-12-23 2022-03-08 交控科技股份有限公司 兼容不同代际车辆的ato停车控制方法

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5360A (en) * 1847-11-06 Cab-wheel
US4263A (en) * 1845-11-08 Improvement in plows
US254033A (en) * 1882-02-21 Car-coupling
CH500196A (de) * 1969-03-10 1970-12-15 Ciba Geigy Ag Verfahren zur Herstellung von neuen Azepinderivaten
US4221887A (en) * 1978-07-17 1980-09-09 Exxon Research & Engineering Co. Plasticization of quaternary phosphonium ion containing polymers
FI75561C (fi) * 1979-10-30 1988-07-11 Ciba Geigy Ag Foerfarande foer framstaellning av 5- karbamoyl-10-oxo-10,11-dihydro-5h-dibens/b,f/azepin och daertill noedvaendiga mellanprodukter.
CH649080A5 (de) * 1981-04-16 1985-04-30 Ciba Geigy Ag 5h-dibenz(b,f)azepin-5-carboxamide als mittel zur prophylaxe und behandlung von zerebraler leistungsinsuffizienz.
US4806410A (en) 1986-09-18 1989-02-21 Ranpak Corp. Processes for the production of antistatic or static dissipative paper, and the paper products thus produced, and apparatus utilized
US4968508A (en) 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
ZA881301B (en) 1987-02-27 1989-10-25 Lilly Co Eli Sustained release matrix formulations
DK130287D0 (da) * 1987-03-13 1987-03-13 Benzon As Alfred Oralt praeparat
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
US5326570A (en) * 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
JPH06199657A (ja) 1992-12-10 1994-07-19 Sumitomo Pharmaceut Co Ltd 徐放性製剤
FR2700117B1 (fr) * 1993-01-07 1995-02-03 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
US5472714A (en) * 1993-09-08 1995-12-05 Ciba-Geigy Corporation Double-layered oxcarbazepine tablets
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
US5700832A (en) * 1994-10-19 1997-12-23 Daewon Pharm. Co., Ltd. Antianemic agent containing iron and difructose
IT1272897B (it) * 1995-01-13 1997-07-01 I F C Iniziative Finanziaarie Processo per la produzione di 10-oxo-10,11-diidro-sh- -dibenz(b,f) azepin-5-carbossiammide
GB9523752D0 (en) 1995-11-21 1996-01-24 Pfizer Ltd Pharmaceutical formulations
US5980942A (en) 1997-01-23 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Zero-order sustained release matrix tablet formulations of carbamazepine
US6296873B1 (en) 1997-01-23 2001-10-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Zero-order sustained release delivery system for carbamazephine derivatives
US20020022056A1 (en) 1997-02-14 2002-02-21 Burkhard Schlutermann Oxacarbazepine film-coated tablets
CO4920215A1 (es) * 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
DE69805001T2 (de) * 1997-12-05 2002-08-22 Alza Corp Osmotische darreichungsform mit zwei mantelschichten
WO2000004879A1 (en) 1998-07-24 2000-02-03 Andrix Pharmaceuticals, Inc. Granule modulating hydrogel system
US20020169145A1 (en) 1998-10-14 2002-11-14 Rajen Shah Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
US7214711B2 (en) * 1998-12-23 2007-05-08 Neurotherapeutics Pharma Llc Method of treating migraine headache without aura
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
US20030180352A1 (en) 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
GB9930058D0 (en) * 1999-12-20 2000-02-09 Novartis Ag Organic compounds
GB0002740D0 (en) * 2000-02-07 2000-03-29 Novartis Ag Organic compounds
GB0018968D0 (en) * 2000-08-02 2000-09-20 Pfizer Ltd Particulate composition
WO2002045695A2 (en) 2000-12-05 2002-06-13 Alexander Macgregor Hydrostatic delivery system for controlled delivery of agent
US6287599B1 (en) 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
WO2002064557A2 (en) * 2001-02-12 2002-08-22 Teva Pharmaceutical Industries Ltd. New crystal forms of oxcarbazepine and processes for their preparation
BR0209845A (pt) 2001-05-18 2004-08-24 Ranbaxy Lab Ltd Formas de dosagem de oxcarbazepina e processo para a preparação das mesmas
WO2003017981A1 (en) 2001-08-29 2003-03-06 Ranbaxy Laboratories Limited Controlled release formulation of clarithromycin or tinidazol
CA2407173C (en) * 2001-10-09 2009-09-29 Max India Limited Process for the preparation of 10-methoxycarbamazepine
US20030113366A1 (en) 2001-12-14 2003-06-19 Macgregor Alexander Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents
KR100540035B1 (ko) * 2002-02-01 2005-12-29 주식회사 태평양 다단계 경구 약물 방출 제어 시스템
US6572889B1 (en) 2002-03-07 2003-06-03 Noveon Ip Holdings Corp. Controlled release solid dosage carbamazepine formulations
US20070021356A1 (en) * 2002-03-18 2007-01-25 Cady Roger K Preemptive prophlyaxis of migraine
DE10224170A1 (de) * 2002-05-31 2003-12-11 Desitin Arzneimittel Gmbh Pharmazeutische Zusammensetzung mit verzögerter Wirkstofffreisetzung
AU2003240654A1 (en) * 2002-05-31 2003-12-19 Desitin Arzneimittel Gmbh Pharmaceutical composition containing oxcarbazepine and having a controlled active substance release
US7091339B2 (en) * 2002-06-14 2006-08-15 Taro Pharmaceuticals Usa, Inc. Method of preparing a 5H-dibenz(b,f)azepine-5-carboxamide
AU2003263760A1 (en) 2002-06-27 2004-01-19 The General Hospital Corporation Methods for the treatment or prevention of obesity
GB0221956D0 (en) * 2002-09-20 2002-10-30 Novartis Ag Organic compounds
US20040058997A1 (en) * 2002-09-24 2004-03-25 David Gordon Daniel Method for treatment of disorders of personal attachment and deficient social interaction
US7259186B2 (en) 2002-12-17 2007-08-21 Abbott Laboratories Salts of fenofibric acid and pharmaceutical formulations thereof
CN100473378C (zh) * 2002-12-17 2009-04-01 阿伯特有限及两合公司 包含非诺贝酸、其生理可接受的盐或衍生物的制剂
US7151114B2 (en) * 2003-01-09 2006-12-19 Boehringer Ingelheim International Gmbh Use of substituted 2-phenylbenzimidazoles as medicaments
DE602004023861D1 (de) * 2003-09-03 2009-12-10 Novartis Ag Verwendung von oxcarbazepin zur verbesserung des schlafes bei patienten die an chronischem schmerz leiden
JP2005104914A (ja) 2003-09-30 2005-04-21 Kyowa Yakuhin Kogyo Kk 塩基性薬剤含有製剤
CA2471666C (en) * 2004-06-18 2009-10-13 Apotex Pharmachem Inc. An improved process for the preparation of oxcarbazepine and related intermediates
GB0512324D0 (en) * 2005-06-16 2005-07-27 Novartis Ag Organic compounds
US20060166968A1 (en) * 2004-07-16 2006-07-27 Sundaram Venkataraman Crystalline form of oxcarbazepine
US20070032647A1 (en) * 2004-10-15 2007-02-08 Amoli Organics Ltd. Novel process for preparation of 10-oxo-10, 11-dihydro-5h-dibenz [b,f] azepine-5-carbox- amide (oxcarbazepine) via intermediate, 10-methoxy-5h-debenz[b,f] azepine-5-carbonyl- chloride
US20060111343A1 (en) * 2004-11-01 2006-05-25 Glenmark Pharmaceuticals Limited Oxcarbazepine dosage forms
GB2422149A (en) 2005-01-14 2006-07-19 Portela & Ca Sa Process for the preparation of 10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide
WO2006080029A1 (en) 2005-01-27 2006-08-03 Alembic Limited Extended release formulation of levetiracetam
US20070014864A1 (en) * 2005-07-15 2007-01-18 Teva Pharmaceutical Industries, Ltd. Novel pharmaceutical granulate
US20070014854A1 (en) * 2005-07-15 2007-01-18 Ilan Zalit Novel granulation process
US20070059354A1 (en) * 2005-07-29 2007-03-15 Sankar Ramakrishnan Sustained release dosage forms of oxcarbazepine
US20070092559A1 (en) * 2005-10-24 2007-04-26 Jinghua Yuan Liquid dosage forms having enteric properties of delayed and then sustained release
US20070104778A1 (en) * 2005-11-07 2007-05-10 Hongxia Zeng Controlled-release emulsion compositions
US20070148245A1 (en) * 2005-12-22 2007-06-28 Ilan Zalit Compressed solid dosage forms with drugs of low solubility and process for making the same
CA2597740C (en) 2006-04-26 2012-10-16 Supernus Pharmaceuticals, Inc. Modified-release preparations containing oxcarbazepine and derivatives thereof

Also Published As

Publication number Publication date
JP2009535351A (ja) 2009-10-01
US20150099739A1 (en) 2015-04-09
US20190381063A1 (en) 2019-12-19
US20090004263A1 (en) 2009-01-01
AU2007242984A1 (en) 2007-11-08
US20210038613A1 (en) 2021-02-11
US20210236510A1 (en) 2021-08-05
US11896599B2 (en) 2024-02-13
EP2026815B1 (de) 2011-01-26
US20090005360A1 (en) 2009-01-01
JP2013079267A (ja) 2013-05-02
ES2396051T3 (es) 2013-02-18
US20170056411A1 (en) 2017-03-02
US8617600B2 (en) 2013-12-31
US7910131B2 (en) 2011-03-22
MX2008013675A (es) 2009-03-06
US20150094301A1 (en) 2015-04-02
US9855278B2 (en) 2018-01-02
CN101489560A (zh) 2009-07-22
CN101489560B (zh) 2015-11-25
US9370525B2 (en) 2016-06-21
US11166960B2 (en) 2021-11-09
US9351975B2 (en) 2016-05-31
US20180098996A1 (en) 2018-04-12
JP5253381B2 (ja) 2013-07-31
US20120232060A1 (en) 2012-09-13
EP2026815A1 (de) 2009-02-25
CA2597740A1 (en) 2007-10-26
DE602007012236D1 (de) 2011-03-10
WO2007127630A1 (en) 2007-11-08
US8017149B2 (en) 2011-09-13
US10220042B2 (en) 2019-03-05
US20230081113A1 (en) 2023-03-16
US20140100219A1 (en) 2014-04-10
US8211464B2 (en) 2012-07-03
US20150359800A1 (en) 2015-12-17
EP2359830A1 (de) 2011-08-24
US9119792B2 (en) 2015-09-01
ES2360423T3 (es) 2011-06-03
US7722898B2 (en) 2010-05-25
AU2007242984B2 (en) 2012-11-08
US20150359748A1 (en) 2015-12-17
US20210308142A9 (en) 2021-10-07
US20110301147A1 (en) 2011-12-08
US8821930B2 (en) 2014-09-02
US20070254033A1 (en) 2007-11-01
EP2359830B1 (de) 2012-09-19
CA2597740C (en) 2012-10-16
US9119791B2 (en) 2015-09-01

Similar Documents

Publication Publication Date Title
ATE496623T1 (de) Oxcarbazepin-zubereitungen für kontrollierte freisetzung mit sigmoidalem freisetzungsprofil
CY1125077T1 (el) Αγωγη της ανεπαρκειας και ελλειψης βιταμινης d με 25-υδροξυβιταμινη d2 και 25-υδροξυβιταμινη d3
LTPA2017009I1 (lt) Brutono tirozinkinazės inhibitoriai
CL2008001932A1 (es) Compuestos derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b]piridazina, inhibidores de cq1epsilon y/o ck1delta; procedimiento de preparacion; composicion farmaceutica que los comprende; y uso en el tratamiento de desordenes del sueno, trastorno del ritmo circadiano, cancer y enfermedad de alzheimer.
ECSP066365A (es) Anilino purinas sustituidas en la posición 6 útiles como inhibidores de rtk
ECSP10010548A (es) Composiciones y metodos de preparacion y uso de las mismas
CY1117667T1 (el) 3,4-διαρυλπυραζολια ως αναστολεις κινασης πρωτεϊνης
DE602006014579D1 (de) Heteroalkylgebundene pyrimidinderivate
ECSP088763A (es) Nuevas combinaciones terapéuticas para el tratamiento de la depresión
NO20090623L (no) Forbindelser for behandling av proliferative lidelser
DE602005006815D1 (de) 2-carbamid-4-phenylthiazol-derivate, deren herstellung und therapeutische verwendung
UA109878C2 (uk) Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти)
NO20091509L (no) Substituerte tetrahydropyrrolopyrazinforbindelser med affinitet KCNQ2/3 K+ kanal og anvendelse derav i medikamenter
DE602005002470D1 (de) 1-aminophthalazinderivate, deren herstellung und deren therapeutische verwendung
BRPI0607198A2 (pt) composição, uso da composição método de tratamento doenças, e, embalagem farmacêutica
ATE477805T1 (de) 9a-carbamoyl-y-aminopropyl- und 9a-thiocarbamoyl- y-aminopropyl-azalide mit antimalaria-aktivität
UY31305A1 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmacéuticas que las contienen.
BRPI0911203A2 (pt) peptídeo ou derivado de peptídeo, composição farmacêutica, uso de um peptídeo ou derivado de peptídeo, métodos para tratar um paciente tendo uma deficiencia e para preparar o peptídeo ou derivado de peptídeo.
ATE512970T1 (de) Dimere von artemisininderivaten, deren herstellung und deren therapeutische verwendung
MX2010006204A (es) Derivados de oxindol 5,6-disubstituidos y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
DE602005010744D1 (de) Piperazinylpyridinderivate als mittel gegen adipositas
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
NO20092073L (no) Modulatorer av C3A-reseptor, og fremgangsmater for anvendelse derav
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
DE602005011818D1 (de) Aminotropanderivate, deren herstellung und deren therapeutische verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties